Genzyme’s Synvisc-ONE and Myozyme Could Both See Delays After Advisory Committees

A Dec. 9 advisory committee meeting for the osteoarthritis pain management candidate leaves two weeks for FDA turnaround by the product’s action date.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet